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Abstract
Background: Dysregulation of epidermal growth factor and insulin-like growth factor signaling play important
roles in human hepatocellular carcinoma (HCC), leading to frequent activation of their downstream targets, the ras/
raf/extracellular signal-regulated kinase (ERK) and the phosphoinositide 3-kinase (PI3K)/Akt/mammalian Target of
Rapamycin (mTOR) pathways. Salirasib is an S-prenyl-cysteine analog that has been shown to block ras and/or
mTOR activation in several non hepatic tumor cell lines. We investigated in vitro the effect of salirasib on cell
growth as well as its mechanism of action in human hepatoma cell lines (HepG2, Huh7, and Hep3B) and its in vivo
effect in a subcutaneous xenograft model with HepG2 cells.
Results: Salirasib induced a time and dose dependent growth inhibition in hepatocarcinoma cells through
inhibition of proliferation and partially through induction of apoptosis. A 50 percent reduction in cell growth was
obtained in all three cell lines at a dose of 150 μM when they were cultured with serum. By contrast, salirasib was
more potent at reducing cell growth after stimulation with EGF or IGF2 under serum-free conditions, with an IC50
ranging from 60 μMt o8 5μM. The drug-induced anti-proliferative effect was associated with downregulation of
cyclin A and to a lesser extent of cyclin D1, and upregulation of p21 and p27. Apoptosis induction was related to a
global pro-apoptotic balance with caspase 3 activation, cytochrome c release, death receptor upregulation, and a
reduced mRNA expression of the apoptosis inhibitors cFLIP and survivin. These effects were associated with ras
downregulation and mTOR inhibition, without reduction of ERK and Akt activation. In vivo, salirasib reduced tumour
growth from day 5 onwards. After 12 days of treatment, mean tumor weight was diminished by 56 percent in the
treated animals.
Conclusions: Our results show for the first time that salirasib inhibits the growth of human hepatoma cell lines
through inhibition of proliferation and induction of apoptosis, which is associated with ras and mTOR inhibition.
The therapeutic potential of salirasib in human HCC was further confirmed in a subcutaneous xenograft model.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide, and the third leading cause of
cancer related mortality. Its incidence has more than
doubled during the last two decades in the western
world, where it is the fastest growing cause of cancer
related death [1]. Despite the magnitude of the problem,
existing therapies are of limited efficacy. No more than
30% of the patients are eligible for curative treatment,
and recurrence is a frequent issue affecting up to 70% of
the patients after tumor ablation. Moreover, due to
underlying cirrhosis, systemic therapy with classical
cytotoxic drugs is poorly tolerated and ineffective [2].
Accordingly, new therapeutic approaches for this disease
are eagerly awaited.
Several growth factor signaling pathways are dysregu-
lated in hepatocarcinogenesis [3]. In particular, altered
intracellular signaling elicited by epidermal growth fac-
tor (EGF), insulin-like growth factor (IGF) and Vascular
Endothelial Growth Factor have been involved in the
pathogenesis of HCC. Hence, inhibitors of their recep-
tors are under intense investigation. While anti-IGF
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in preclinical and early clinical trials, inhibition of the
EGF receptor (EGFR) by either tyrosine kinase inhibitors
or monoclonal antibodies has shown limited efficacy in
several phase II studies in HCC [4]. In non hepatic
epithelial tumor cell lines, inhibition of EGFR or IGF-1R
individually promotes activation of the reciprocal recep-
tor [5] and IGF-2 overexpression has been involved in
the resistance of HCC to EGFR inhibition in a rat
model [6]. Treatment interfering with both receptors
could thus represent a better strategy to treat this dis-
ease. Alternatively, targeting one or several of their
downstream signaling pathways could be an elegant way
to block growth factor signaling. Among those, both
ras-raf-MEK-ERK and PI3K-Akt-mTOR pathways are
activated upon EGFR and IGF-1R stimulation. While ras
activation upon EGFR stimulation induces PI3K activa-
tion [7], IGF-1R is able to activate the PI3K-Akt-mTOR
pathway independently of ras [8].
Ras activation has been shown to be an ubiquitous
and early event in human HCC [9], whereas mTOR acti-
vation is present in half of the cases [10]. Downstream
receptor signaling inactivation has proved its efficacy as
demonstrated by the results of the SHARP trial evaluat-
ing sorafenib, a multikinase inhibitor targeting the
VEGFR and PDGFR kinases as well as raf, in advanced
HCC. However, it only leads to a modest increase in
median overall survival of 3 months [11], highlighting
the need for the development of new and more effective
targeted therapies for HCC.
Salirasib (Farnesylthiosalicylic acid, FTS) is a S-farnesyl
cysteine analog that affects docking of active GTP-
bound ras in the cell membrane by competing with ras
for its membrane anchorage sites and consequently inhi-
bits ras-dependent cell growth [12]. In cell lines, this
leads to an accelerated degradation of cytosolic ras and
a decrease in the total amount of cellular ras [13]. This
mode of action affecting all ras isoforms differentiates
salirasib from farnesyltransferase inhibitors, which fail to
block K-ras and N-ras activity because they undergo
geranylgeranylation following treatment with those
molecules [7]. In addition, salirasib has also been shown
to directly inhibit mTOR complex 1 activity by disrup-
tion of the mTOR-raptor complex [14]. It exhibits anti-
tumoral effects in several non-liver cancer cell lines [15]
and has recently been evaluated in a phase 1 study in
patients with solid non hepatic tumors, showing that it
was well tolerated [16]. Targeting both ras and mTOR,
along with a good tolerance in patients, make salirasib a
good candidate for HCC therapy.
Previous work of our team has shown that high dose
salirasib blocks hepatocytes proliferation in vivo in rats
after partial hepatectomy [17]. This inhibitory effect was
at least partially mediated by inhibition of ERK
phosphorylation. More recently, we have shown that sal-
irasib administration prevents liver tumor development
in a model of diethylnitrosamine-induced hepatocarci-
nogenesis in rats [18].
The aims of the present study are to evaluate the effi-
cacy of salirasib in human HCC cell lines, and to under-
stand its underlying molecular mechanisms of action in
these particular cells thereby providing a rationale for
testing it as a novel anti-cancer treatment in HCC clini-
cal trials.
Methods
Compounds
Salirasib was kindly provided by Concordia Pharmaceuti-
cals (Fort Lauderdale, Florida, USA). Unless stated other-
wise, all cell culture reagents and growth factors were
purchased from Invitrogen (Brussels, Belgium). Antibodies
were from Santa Cruz (Santa Cruz, California, USA), Milli-
pore (Billerica, Massachusetts, USA), Cell Signaling (Dan-
vers, Massachusetts, USA), BD Biosciences (Erembodegem,
Belgium), or Sigma-Aldrich (Bornem, Belgium).
Cell culture
HepG2, Huh7 and Hep3B were obtained from European
Collection of Cell Culture (Salisbury, United Kingdom)
a n dc u l t u r e di nD u l b e c c o ’sm o d i f i e de a g l em e d i u m
(HepG2 and Huh7) or minimum essential medium con-
taining Earle’s salt (Hep3B) supplemented with 10% fetal
bovine serum (FBS), 1% streptomycin and penicillin, 1%
non essential amino-acid, plus 1% sodium pyruvate for
HepG2, in 5% CO2 at 37°C. Medium was renewed once
a day. Cells were seeded in 6-well plates (cell count, cell
cycle analysis, RNA isolation) or in 96-well plates
(WST-1, BrdU, caspase, and LDH assays) at a density of
1-5 × 10
5 and 5 × 10
3cells per well, respectively. For
protein preparation, cells were plated in 10 cm Petri
dishes at a density of 1.5 × 10
6 (4.5 × 10
6 for ras pull-
down assays). Cells were allowed to adhere overnight.
Thereafter, they were incubated in medium supplemen-
ted with 0.1% dimethylsulfoxyde (DMSO, vehicle) or sal-
irasib (50 μM, 100 μM or 150 μM) for various durations
(2 hours to 7 days). For IC50 determination, salirasib
concentrations ranging from 25 μMt o2 0 0μMw e r e
used. Analyses of cell cycle, RNA and protein were per-
formed in cells exposed to DMSO or 150 μM salirasib
during 24 h or 48 h (and 72 hours for cell cycle), for
this concentration corresponded to IC50 in all 3 tested
cell lines (figure 1A-C).
For growth factor simulation, cells were serum starved
overnight. EGF (50 ng/ml) or IGF2 (75 ng/ml) were
added to serum-free medium supplemented with 0.1%
bovine serum albumin (BSA) and cells were stimulated
for 2 minutes (ras pull-down assays), 10 minutes (signal-
ing pathway studies), 24 hours (cell proliferation studies)
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irasib or DMSO.
All experiments were repeated at least twice on sepa-
rate days. The total n used for statistical analysis was 6
or 8 per treatment group.
Growth inhibition studies
For time dependent response studies, cells were har-
vested with 0.05% Trypsin-EDTA daily for 1 to 7 days
and counted under the microscope using the Trypan
blue exclusion method.
For dose response studies, cells were incubated in
medium supplemented with salirasib or DMSO for 3
days. Cell viability was determined using a colorimetric
WST-1 assay (Roche, Vilvoorde, Belgium) according to
the manufacturer’s instructions. The IC50 value, at
which 50% of the cell growth is inhibited compared
with DMSO control, was calculated by nonlinear regres-
sion analysis using GraphPad Prism software (San
Diego, California, USA).
Determination of DNA synthesis
DNA synthesis was assessed after 1 and 2 days of treat-
ment by a colorimetric Bromodeoxyuridine (BrdU) assay
(Roche) according to the manufacturer’s instructions.
BrdU was added for the last 4 h of the experiment.
Cell cycle analysis
Cell cycle was analyzed after 1, 2 and 3 days of treat-
ment. Briefly, cells were harvested by trypsinization and
washed with PBS. They were fixed in ice-cold ethanol,
washed, resuspended in PBS and treated with RNase A
(Sigma-Aldrich). Finally, cells were stained with propi-
dium iodide (Sigma-Aldrich) and analyzed by flow cyto-
metry (BD FACSCalibur, BD Biosciences). DNA content
was quantified using CellQuest Pro software (BD
Biosciences).
Determination of caspase-3/7 activity and LDH release
Caspase activity and LDH release were assessed after
24 h of treatment using the Caspase-Glo 3/7 assay (Pro-
mega, Leiden, Netherlands) and the Cytotoxicity Detec-
tion KitPlus (Roche), respectively, according to the
manufacturer’s instructions.
Western blotting
Cells were harvested in ice-cold lysis buffer [0.1% Triton
X-100, 50 mM HEPES (pH 7.5), 150 mM NaCl, 10%
(v/v) glycerol, 1.5 mM MgCl2, 1 mM dithiothreitol, 1
mM sodium fluoride, 0.1 mM sodium orthovanadate, 1
mM phenylmethylsulfonyl fluoride, 2 μg/ml leupeptin
and aprotinin]. Equal amounts of proteins, determined
by a BCA protein assay (Pierce, Rockford, Illinois, USA),
were separated by SDS/PAGE and transferred on to
polyvinylidene fluoride membranes according to stan-
dard techniques. Primary and secondary antibodies as
well as working conditions are listed in Additional file 1,
Table S1. Membranes were revealed with the ‘Western
Lightning Chemiluminescent Reagent Plus’ (Perkin
Elmer, Boston, MA, USA) detection system and immu-
noreactive proteins were quantified by densitometry
using the Gel Doc™ XR System 170-8170 device and
software (Bio-Rad, Nazareth, Belgium) and normalized
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Figure 1 Salirasib induces a dose- and time-dependent
decrease in HCC cells viability. A-C. HepG2 (A), Huh7 (B), and
Hep3B (C) cells were plated in 96-wells plates and incubated with
various doses of salirasib for 3 days (n = 8 at each dose). Cell
viability was assessed by WST-1 expression and IC50 was determined
using nonlinear regression analysis. Identical experiments were
performed in FBS-cultured cells as well as in EGF- and IGF2-
stimulated cells. Data are presented as mean ± SEM.
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Page 3 of 14to their respective loading controls, HSP90 or b-actin. In
order to compare the independent experiments, data
were expressed as relative change compared to the con-
trol (DMSO) group which was arbitrarily set at 1 for
each experiment.
Ras pull down assay
Cells were harvested in ice-cold Mg2+ lysis/wash buffer
(Millipore, Cat.# 20-168)s u p p l e m e n t e dw i t h1m M
sodium fluoride, 0.1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, 2 μg/ml leupeptin and
aprotinin. Lysates were centrifuged at 4°C and superna-
tant containing 500 μg of proteins was mixed with 10 μl
of Raf1-ras-binding-domain agarose beads (Millipore,
Cat.# 14-278), rotated at 4°C for 1 hour, washed three
times with lysis/wash buffer, boiled for 5 minutes in
Laemmli buffer under reducing conditions, and sepa-
rated by SDS/PAGE. Activated ras protein was then
revealed by immunoblotting with a pan-ras antibody
(Millipore, Cat.# 05-516).
Reverse transcription and quantitative PCR
Cells were harvested in Trizol Reagent (Invitrogen) for
RNA extraction. RNA was reverse transcribed and sub-
jected to quantitative PCR with the StepOnePlus™ Real
Time PCR System (Applied Biosystems, Lennik, Bel-
gium) using SYBRgreen. Primers were designed using
the Primer Express™ design software (Applied Biosys-
tems, Lennik, Belgium) and sequences are presented in
Additional file 2, Table S2. Quantification was obtained
according to the ΔΔCT method [19]. The final result of
each sample was normalized to its respective Ribosomal
protein L19 (RPL19, internal standard) value.
Tumor xenograft experiments
Six week old female athymic NMRI nu/nu mice (Elevage
Janvier, Le Genest-St-Isle, France) were housed in filter-
topped cages and received food and water ad libitum.
Tumors were generated by subcutaneous injection into
the right lower flank with 5 × 10
6 HepG2 cells sus-
pended in 100 μl PBS in 12 mice. Two weeks after cell
inoculation, when palpable tumours were established,
mice were separated into salirasib-treated (n = 6) and
control group (n = 4). Two animals did not develop
tumours at that time point and had to be excluded from
the study. They received daily i.p. injections of 10 mg/kg
salirasib or a similar volume of vehicle solution (PBS
containing 2.5% v/v ethanol, pH 8.0) for 12 days. Tumor
dimensions were recorded three times per week with a
digital calliper starting with the first day of treatment.
Tumor volumes were estimated as follows: V (mm³) =
(length × width²)/2. Tumour weights were recorded at
the time of sacrifice in order to evaluate treatment
response. The animals were handled according to the
guidelines for humane care for laboratory animals estab-
lished by the Université Catholique de Louvain in accor-
dance with EU regulation. The study protocol was
approved by the local ethics committee.
Statistical analysis
Results are expressed as relative change compared with
DMSO controls and are given as the mean ± SEM. The
statistical differences between groups were tested using
a two-tailed Student’s t test. Statistical significance was
assumed for P values <0.05.
Results
Salirasib induces a dose- and time-dependent decrease
of cell growth in HCC cells
Incubation of FBS-cultured cells with salirasib for 3
days resulted in a dose-dependent growth inhibition
with an IC50 of 149 μM in HepG2, 145 μM in Huh7,
and 153 μM in Hep3B (figure 1A-C). As FBS is a cock-
tail of growth factors and cytokines recruiting multiple
receptors, we hypothesized that salirasib would be more
effective in reducing cell growth in serum starved cells
that were selectively exposed to EGF or IGF2 only.
Indeed, we observed that salirasib treatment elicited a
dose-dependent decrease in cell viability in all 3 cell
lines that was more pronounced in both EGF- and
IGF2-stimulated cells than in FBS-stimulated cells.
Respectively, IC50 in EGF- and IGF2- stimulated cells
decreased to 59 μMa n d8 5μM for HepG2, to 81 μM
and 85 μMf o rH u h 7 ,a n dt o6 7μMa n d8 6μMf o r
Hep3B (figure 1A-C).
In time-course experiments with FBS-cultured cells,
we found that 150 μM salirasib led to a statistically sig-
nificant reduction in cell number already after 24 hours
of treatment in all three cell lines, while 3 and 4 days
were necessary to obtain a significant reduction in cell
number in cells exposed to 100 μM and 50 μM salirasib,
respectively (data not shown). After 7 days, cell counts
were reduced to 31% of controls in Hep3B cells treated
with 50 μM salirasib and to 5% of controls when they
were exposed to 100 μM salirasib. In HepG2 cells, cell
counts dropped to 54% and 34% of controls when trea-
ted with 50 μMa n d1 0 0μM salirasib, respectively. In
Huh7 cells, the same concentrations of salirasib
decreased cell numbers to 70% and 52% of untreated
cells, respectively. In the three tested cell lines, no more
viable cells were present when exposed to 150 μMs a l i r -
asib for one week (table 1).
Salirasib reduces cell proliferation through modulation
of cell cycle effectors and inhibitors
We next assessed the impact of salirasib on cell prolif-
eration by measuring BrdU incorporation. We observed
a time- and dose-dependent decrease in DNA synthesis
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cell proliferation. After 24 hours of treatment in FBS-
incubated cells, reduction in cell proliferation was only
seen in cells exposed to 150 μM salirasib. After 48
hours however, a significant decrease in BrdU incor-
poration was present at 100 μM in all the tested cell
lines and to a lesser extent at 50 μM in Huh7 and
Hep3B cells. Inhibition of proliferation was further
investigated in EGF- and IGF2-stimulated cells. By con-
trast to cells incubated with FBS, reduction in BrdU
incorporation occurred earlier and at a lower concentra-
tion of salirasib in growth factor stimulated cells.
Already after 24 hours of treatment, 100 μM salirasib
markedly decreased EGF- (figure 2D-F) and IGF2-
induced (figure 2G-I) DNA synthesis in HepG2 and
Hep3B cells. In Huh7 cells, significant inhibition was
even apparent at 50 μM.
K-ras activation is known to regulate cell cycle pro-
gression through interference with cyclins and cell cycle
inhibitors [20], whereas salirasib has been shown to up-
regulate p53 and p21 [21]. The levels of cyclin A, cyclin
D1, cyclin E, Cdk2, Cdk4, p27 and p53 were thus evalu-
ated by Western blot analysis, and expression of p21
was assessed by quantitative PCR.
Compared with untreated controls, salirasib induced
no significant changes in cyclin E and Cdk2 expression.
Cdk4 expression was down-regulated after 2 days of
treatment only in Huh7 cells (figure 3A). The most pro-
minent changes in expression of cell cycle effectors were
observed for cyclin A and cyclin D1 (figure 3A-D). After
48 hours of treatment, we observed a significant down-
regulation of cyclin A in all tested cell lines. Moreover,
a significant decrease was already seen in Huh7 cells
after 24 hours of treatment, as well as in Hep3B cells,
however without reaching statistical significance in the
latter cell line (P = 0.067). Cyclin D1 was blunted in
Hep3B cells as from 24 hours of treatment onwards. A
slight but significant reduction was also observed in
Huh7 cells after 48 hours, while salirasib did not modify
cyclin D1 expression in HepG2 cells.
Expression of the cell cycle inhibitors p27 and p21
was increased by salirasib in HepG2 and Hep3B cells,
while p27 remained unchanged and p21 decreased in
Huh7 cells (figure 3A-E). p53 expression was markedly
down-regulated after 2 days of treatment in HepG2
cells (p53 wild-type). By contrast, the strong basal
expression seen in the p53-mutated Huh7 cell line was
not modified by salirasib (figure 3A-C). As expected,
p53 immunoreactivity was absent in the p53-null
Hep3B cell line (figure 3A).
Since our results suggested that salirasib might inter-
fere with the cell cycle, we assessed cell cycle distribu-
tion by flow cytometry. Salirasib elicited an increase of
the percentage of cells in G0/G1 phase and a concomi-
tant decrease of the percentage of cells in S and G2/M
phases (Additional file 3, figure S1). Those changes were
already statistically significant after 1 day in Huh7 and
after 2 days in HepG2, but only after 3 days in Hep3B
cells (data not shown). After 3 days of treatment, 61% of
HepG2 cells in the control group were in G0/G1 phase,
16% in S phase and 22% in G2/M phases. By contrast,
the percentage of cells in G0/G1 phase increased to
68%, whereas it decreased to 12% and 18% for S and
G2/M phases, respectively, in salirasib treated cells. In
Huh7 cells, the percentage of cells in G0/G1 phase rose
from 49 to 54 after three days of treatment. Concomi-
tantly, the proportion of cells in S phase dropped from
26% to 16%, and that of cells in G2/M phases from 23%
to 15%. In Hep3B cells, the proportion of cells in G0/
G1, S and G2/M phases was 54%, 12% and 28%, respec-
t i v e l y ,i nc o n t r o lc e l l sa n dc h a n g e dt o5 7 % ,1 0 % ,a n d
27%, respectively, in salirasib treated cells. Additionally,
salirasib induced an increase in the percentage of sub-
G0 cells from 2% to 14% in Huh7 and from 5% to 8% in
Hep3B cells.
Salirasib induces apoptosis in HepG2 and Hep3B cells
As caspase-3 and -7 are the principal effector caspases
committing cells to apoptosis [22], we studied their
activity upon salirasib treatment in FBS-cultured cells.
After 24 hours, it induced a marked increase of caspase-
3/7 activity in HepG2 cells (up to 22-fold increase at
150 μM) and a more modest but significant increase in
Hep3B cells (2.2 fold increase at 150 μM) (figure 4A, C).
Caspase-3/7 was not activated in Huh7 cells (figure 4B).
Apoptosis induction was further substantiated by an
increase cytochrome c expression detected by western
blot analysis (Figure 4D) in HepG2 and Hep3B but not
in Huh7 cells, pointing to a possible involvement of the
mitochondrial apoptotic pathway. At the same time-
point, no LDH activity could be detected in the culture
medium of any of the three tested cell lines whether
treated or not with salirasib (data not shown).
As our results suggest activation of the intrinsic apop-
totic pathway, we studied the expression of Mcl1, Bcl-
XL, and survivin all of which inhibit this pathway,
by Western blot or quantitative PCR. Among the
Table 1 Salirasib induced decrease in cell number after
7 days of treatment
Salirasib treatment
50 μM 100 μM 150 μM
HepG2 (S.E.M.) 54%*** (±5%) 34%*** (±3%) 2%*** (±0%)
Cell line Huh7 (S.E.M.) 70%** (±6%) 52%*** (±3%) 1%*** (±0%)
Hep3B (S.E.M.) 31%*** (±3%) 5%*** (±0%) 0%***
Data (means ± S.E.M.) are expressed as relative change compared with the
control group (DMSO) ** P < 0.01 and *** P < 0.001.
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Page 5 of 14anti-apoptotic members of the Bcl2 family shown to be
modified in HCC [23], salirasib significantly reduced
Mcl1 expression in Huh7 and Hep3B but not in HepG2
cells, while Bcl-XL levels remained unchanged upon
treatment in the three tested cell lines (figure 5A-B).
The caspase-3, -7, and -9 inhibitor survivin was strongly
repressed in all treated cell lines compared to control
(figure 5C).
In addition, since we have previously shown that salir-
asib induced apoptosis in preneoplastic liver lesions in a
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Figure 2 Salirasib inhibits HCC cells proliferation. HepG2 (left column), Huh7 (central column), and Hep3B (right column) cells were seeded
in 96-wells plates and incubated with DMSO (control) or the indicated doses of salirasib (n = 8 at each dose and time-point). Identical
experiments were performed in FBS-cultured cells (A-C), in EGF- (D-F) and IGF2-stimulated (G-I) cells. BrdU incorporation was assessed after
1 (FBS, EGF, IGF2) or 2 days (FBS only) treatment with salirasib. In the growth factor stimulation experiments, a FBS group - consisting of FBS-
cultured untreated cells - was included as a positive control. Data are presented as mean ± SEM. * P < 0.05, ** P < 0.01 and *** P < 0.001 in
treated groups versus control group.
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Page 6 of 14rat model of HCC in vivo through activation of the
extrinsic apoptotic pathway [18], we studied expression
of cellular FLICE-like inhibitory protein (cFLIP), TNF-
related apoptosis inducing ligand (TRAIL)-receptor 1
(DR4), TRAIL-receptor 2 (DR5), tumor necrosis factor
(TNF)-a, and Fas by quantitative PCR in our human
HCC cell lines. The caspase-8 inhibitor c-FLIP was
downregulated in Huh7 and Hep3B, but not in HepG2
cells (figure 5C). Expression of the pro-apoptotic
TRAIL-receptor DR4 and DR5 mRNA levels were upre-
gulated upon treatment in HepG2 and Hep3B, but not
in Huh7 cells (figure 5D). Salirasib treatment elicited a
dramatic increase in TNFa mRNA expression in Hep3B
cells, while it remained unchanged in Huh7 and was
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Page 7 of 14downregulated in HepG2 cells (figure 5D). Finally, Fas
expression was increased upon treatment in HepG2 (1.5
fold compared to control, P < 0.05). As Huh7 and
Hep3B cells are known to be Fas-deficient, we did not
evaluate it in those cell lines. Altogether our results sug-
gest that salirasib induce a pro-apoptotic phenotype
with some differences among the 3 cell lines (table 2).
Salirasib reduces ras expression and activation in
HCC cells
As salirasib is known to inhibit ras activity and to promote
its degradation, we studied its impact on ras expression in
FBS-cultured cells by Western blot and quantitative PCR
[13]. Exposure of cells to salirasib for 48 hours decreased
ras protein expression in all three cell lines. Moreover this
was already detectable after 24 hours in Huh7 and Hep3B
but not in HepG2 cells (figure 6A-B). Decreased ras pro-
tein levels were not related to repression of H-ras or K-ras
gene transcription (figure 6C).
To further confirm the impact of salirasib on ras acti-
vation, a ras pull-down assay was performed in HepG2
cells stimulated with EGF or IGF2 after 2 hours of incu-
bation with DMSO or salirasib (figure 6D). EGF induced
a strong activation of ras compared to serum-starved
cells whereas activated ras after IGF2 stimulation
remained at the level of unstimulated cells. Salirasib
strongly reduced EGF-induced ras activation, and also
decreased the expression of activated ras observed in
IGF2-stimulated cells.
The growth inhibitory effect of salirasib in HCC cell lines
is associated with mTOR inhibition independent of ERK or
Akt activation
In order to evaluate the impact of salirasib on ras
mediated signaling, changes in the phosphorylation
levels of key proteins were determined upon EGF- and
IGF2-stimulation in our cell lines. ERK phosphorylation
was used to monitor Raf/MAPK pathway activation, Akt
and glycogen synthase kinase-3b (GSK3b) phosphoryla-
tion were used to measure PI3K/Akt activation, and p70
S6 kinase (p70) was used as a surrogate marker for
mTOR activation.
In all 3 cell lines, EGF stimulation elicited a marked
increase in ERK phosphorylation and preincubation with
salirasib failed to reduce ERK phosphorylation (figure 7,
additional file 4 - figure S2 and additional file 5 - figure
S3). IGF2 stimulation did not induce ERK phosphorylation
compared to controls, and treatment with salirasib prior to
IGF2 increased phospho-ERK expression in HepG2 and
Hep3B cells but not in Huh7 cells compared with controls
and untreated IGF-stimulated cells (figure 7, additional file
4 - figure S2 and additional file 5 - figure S3).
The impact of treatment on Akt phosphorylation was
dependent upon the cell line and culture condition. EGF
induced Akt phosphorylation at Thr308 and Ser473 in
all three cell lines. Pre-treatment with salirasib strongly
reduced EGF-induced Akt phosphorylation in HepG2
cells (figure 7), but not in Hep3B or Huh7 cells
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Page 8 of 14(additional file 4 - figure S2 and additional file 5 - figure
S3). IGF2 stimulated Akt phosphorylation in HepG2
and Hep3B cells that was not affected by pre-treatment
with salirasib. By contrast, IGF2 did not increase Akt
phosphorylation over controls in Huh7 cells but pre-
treatment with salirasib induced Akt phosphorylation
compared to controls as well as untreated IGF2 stimu-
lated cells (additional file 4 - figure S2).
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Page 9 of 14Variations in GSK3b phosphorylation levels paralleled
those of Akt (figure 7).
Phosphorylation of p70 was low in unstimulated
HepG2 and Hep3B cells but high in Huh7 cells. EGF sti-
mulation induced phosphorylation of p70 in HepG2 and
Hep3B, and to a lesser extent in Huh7 cells. IGF2 sti-
mulation induced p70 phosphorylation in HepG2 and
Hep3B cells, but did not further increase phospho-p70
levels above the already high baseline expression in
Huh7. Importantly, salirasib abrogated p70 phosphoryla-
tion whether induced by EGF or IGF2 in HepG2 and
Hep3B cells and completely suppressed baseline phos-
pho-p70 expression in IGF2-stimulated Huh7 cells.
Salirasib inhibits tumour growth in a subcutaneous
xenograft model
Finally, we assessed the in vivo antitumor activity of salir-
asib in a subcutaneous xenograft model of HepG2 cells
in nude mice. From 5 days of treatment onwards, salira-
sib induced a statistically significant decrease in tumour
volume (figure 8A). After 12 days of salirasib treatment,
the mean tumour weight was 131.7 ± 18.9 mg compared
with 297.5 ± 48.2 mg in the control group (vehicle), indi-
cating that salirasib reduced tumour growth by 56 per-
cent (figure 8B). Moreover, no overlap in tumour weight
was observed between the control and the treatment
groups, meaning that even the smallest tumour in the
control group remained larger than the biggest tumour
in the treatment group (figure 8C). Animals remained
well throughout the entire experiment and no weight loss
was observed upon treatment, suggesting that salirasib
was well tolerated at this dose regimen (data not shown).
Discussion
Ras and mTOR are regarded as relevant therapeutic tar-
gets in HCC [9,10]. In this study, we report for the first
Table 2 Summary of apoptosis-related changes
HepG2 Huh7 Hep3B
Caspase-3/7 ↑↑↑ – ↑↑
Cytochrome c ↑ (SA) ↑ (SA) ↑ (SA)
Mcl1 – ↓↓
Bcl-XL –––
Survivin ↓↓ ↓ ↓
cFLIP – ↓↓ ↓↓
DR4 ↑↑ – ↑↑
DR5 ↑↑ – ↑↑
TNFa ↓ – ↑↑↑
Fas ↑ NE NE
–: no change; ↑(increase of 1-2x over controls)/↑↑(2-5x)/↑↑↑(>5x); ↓(reduction
<2x compared to controls)/↓↓(reduction >2x compared to control); NE: not
expressed; SA: subjective appraisal. Bold characters: anti-apoptotic. Plain
characters: pro-apoptotic.
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Figure 6 Impact of salirasib on ras expression and activation.
A. Representative Western blots of ras after one and two days of
treatment. B. Western blot of the independent experiments were
quantified by densitometry and then normalized to their respective
b-actin (n = 6 per group) Data are finally expressed as relative
change compared to the control (DMSO) group arbitrarily set at 1.
C. Quantification of H- and K-Ras mRNA expression by quantitative
PCR after one day of treatment with salirasib (n = 6 per group).
Data of the independent experiments were first normalized to
RPL19 (internal standard) and then expressed as relative change
versus control (DMSO) set arbitrarily at 1 (dotted line) and are
presented as mean ± SEM. * P < 0.05, ** P < 0.01 and *** P < 0.001
in treated groups versus control group. D. Representative result of
ras pull-down assays performed in 2 independent experiments in
HepG2 cells stimulated with either EGF or IGF2 and treated with
DMSO or 150 μM salirasib for 2 hours prior to stimulation.
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Page 10 of 14time the effect of salirasib, a novel prenylcysteine analo-
gue inhibiting cell growth in three human HCC cell
lines through interference with ras and mTOR. Even
more importantly, salirasib was able to inhibit both
EGF- and IGF-induced proliferation in human HCC cell
lines, potentially reducing the possibility for escape
mechanisms related to activation of one growth factor
pathway in response to the inhibition of the other one.
Although IC50 were similar after three days of treatment
in the three tested cell lines, time-course experiments
P-Akt (Ser473)
EGF
IGF2
FTS
HepG2
P-ERK
ERK
P-Akt (Thr308)
Akt
P-GSK3b
GSK3b
P-p70
p70
Figure 7 Impact of salirasib on raf/MEK/ERK and PI3K/Akt/
mTOR pathways in HepG2 cells. Representative Western blots of
3 independent experiments of ERK, Akt, GSK3b, p70, and their
phosphorylated counterparts in HepG2 cells stimulated with either
EGF or IGF2 and treated with DMSO or 150 μM salirasib for 2 hours
prior to stimulation Similar changes have been observed in the
other cell lines (see supplementary figures 2 and 3).
Figure 8 Salirasib inhibits tumour growth in a subcutaneous
xenograft model. HepG2 cells were injected subcutaneously in the
lower right flank of female NMRI nude mice. When palpable tumors
were established, mice were treated with 10 mg/kg/day i.p. salirasib
or vehicle for 12 days. A. Tumour volume was assessed three times
per week as described in ‘Materials and Methods’. Data are
presented as mean ± SEM. B. At the end of the treatment period,
animals were sacrificed and tumour weights were recorded. Boxplot
of mean tumor volume at the time of sacrifice. C. Photographs of
the smallest and largest tumours in the control group (CTL) and the
FTS group (salirasib). * P < 0.05 ** P < 0.01 in treated group (n = 6)
versus control group (n = 4).
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Page 11 of 14suggests that Hep3B cells are the most sensitive to salir-
asib among the three tested cell lines, while Huh7 cells
are more resistant. Importantly, our results also demon-
strate that on the long-term salirasib treatment is effec-
tive at doses far below the estimated IC50.
The growth inhibitory effect is mainly mediated by
inhibition of cell proliferation, which is observed in the
three tested cell lines to a similar extent. This reduction
of proliferation is associated with a profound modulation
of the expression of cell cycle mediators. Cyclin A
expression was strongly decreased in HepG2 and Huh7,
and to a lesser extent in Hep3B. In the latter however,
the cell cycle machinery disruption became clearly evi-
dent on the level of cyclin D1, the expression of which
was almost completely abrogated upon treatment. In the
two more sensitive cell lines, HepG2 and Hep3B, expres-
sion of the cell cycle inhibitors p21 and p27 was
increased, reaching the highest magnitude in the most
sensitive Hep3B cells. These observations partially mirror
the impact of activated K-ras on the cell cycle, which is
known to upregulate cyclin A and cyclin D, and to down-
regulate p27 [20]. On the other hand, mTOR inhibitors
are known to induce a G1/S cell cycle arrest through an
increase in p27 and a decrease in cyclin D [24] and cyclin
A [25]. Thus, the impact of salirasib on cell proliferation
might be due to a combination of both previously
described effects of this compound, i.e. ras inhibition and
mTOR inhibition [12,14].
On the other hand, apoptosis also contributes to the
growth inhibitory effect of salirasib, and the relative
resistance of Huh7 compared to the two other cell lines
might be due to the absence of apoptosis induction
upon treatment in these cells. However, the contribution
of apoptosis seems to be less prominent than the anti-
proliferative action of salirasib, at least under our experi-
mental conditions. Indeed, caspase activation is more
pronounced in HepG2 cells than in the more sensitive
Hep3B cells. In addition, in these latter cells, no apopto-
sis induction could be observed at 50 μMo r1 0 0μM
salirasib, although these doses already induce a dramatic
decrease in cell counts over time.
Nevertheless, high dose salirasib elicited caspase-3/7
activation in two cell lines that might at least partially
be mediated by the mitochondrial apoptotic pathway.
Apoptosis could have been caused in our cells by down-
regulation of survivin, as salirasib has been shown to
reduce survivin expression in glioblastoma cells [26],
which was sufficient to elicit apoptosis. In addition, sur-
vivin down-regulation by antisense oligonucleotides has
been shown to inhibit cell growth and to induce apopto-
sis in several cell lines, including HepG2 [27,28]. How-
ever, it was also repressed in the apoptosis-resistant
Huh7 cells, suggesting that additional events are
required to trigger cell death. Our results also suggest
that salirasib might sensitize the cells to death receptor-
induced apoptosis through up-regulation of the TRAIL
receptors DR4 and DR5 in HepG2 and Hep3B cells,
along with increased Fas expression in HepG2 cells and
TNFa induction in Hep3B cells. Fas and TRAIL recep-
tor upregulation alone might, however, not be sufficient
to induce a major impact in vitro for their ligands, FasL
and TRAIL, are mainly expressed on immune cells [29],
which are not present in monocultures. Nevertheless,
up-regulation of death receptors on tumor cells by treat-
ments like salirasib and interaction with their respective
ligands on immune cells could be of major importance
in vivo, further potentiating the anti-tumor effect of
salirasib.
Growth inhibition effects of salirasib are p53-indepen-
dent as salirasib affect in a similar fashion HepG2 (p53
wild type) and Hep3B (p53 null) cells. This is further sub-
stantiated by the decrease in p53 expression observed
after 2 days of treatment in HepG2 cells. This aspect
could be clinically relevant, because most human HCC
harbor defective p53 function [1]. A treatment strongly
depending upon p53 activation could thus be less effec-
tive in these tumors. Our results contrast with a previous
report of increased p53 function in colon cancer cells in
response to salirasib [21]. However, p53 downregulation
is compatible with ras inhibition, because K-ras activation
is known to induce p53 up-regulation [20]. This lack of
p53 upregulation in our study could be related to the
absence of ERK inhibition upon treatment. Indeed, in
HepG2 cells, ERK is a major activator of Mdm2, which is
responsible for p53 degradation [30].
Total Ras protein expression was reduced in the three
tested cell lines after 2 days of treatment, while Ras
mRNA levels remained stable. In addition, salirasib
reduced the expression of active GTP-bound Ras in
HepG2 cells stimulated with EGF. These observations
indicate an increase in ras protein degradation, which is
consistent with the postulated mechanism of action of
salirasib, involving the dislodgement of ras from the cell
membrane followed by a cytosolic degradation [13]. Sur-
prisingly, salirasib was unable to inhibit neither ERK nor
Akt phosphorylation. On the contrary, it even tended to
increase their phosphorylation levels, which could be due
to a strong inhibition of p70 and to the consequent relief
of a negative feedback loop affecting ERK and Akt [31].
Importantly, p70 phosphorylation was abrogated upon
treatment in all cell lines when stimulated with EGF,
which occurred without concomitant inhibition of ERK
or Akt, both of which are known to activate mTOR.
Moreover, salirasib also efficiently reduced p70 phos-
phorylation in all cell lines upon IGF2 stimulation, a
situation where stimulation of the Akt-mTOR axis is
independent of ras activation [8]. Indeed, no ras activa-
tion above baseline levels was observed in HepG2 cells
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Page 12 of 14stimulated with IGF2, and IGF2 did not induce ERK
phosphorylation in any of the tested cell lines. Alto-
gether, these data suggest that salirasib induced inhibi-
tion of mTOR in HCC cells occurs, at least in part,
independently of ras, and thus point to a direct inhibi-
tory effect on the mTOR complex 1, confirming earlier
observations [14].
Nonetheless, it should not be concluded that the
growth inhibitory effect that is observed in HCC cell
lines solely relies on mTOR inhibition, as other unex-
plored ras mediators could be affected. Although, both
ras and mTOR inhibition taken separately could explain
the decrease in cyclin A and the increase in p27 levels,
it is worth to note that these changes parallel the down-
regulation of ras in HepG2 and Hep3B cells.
Finally, we show that salirasib inhibits tumour growth
in vivo in a subcutaneous xenograft model at a well tol-
erated dose. As salirasib is metabolized in the liver by
cytochrome P450 2C subfamily (Concordia Pharmaceu-
tical Inc., personal communication), there might be
some concern about its potential efficacy in this organ.
With regard to maintaining its efficiency in the liver as
a target organ, we have shown that low-dose of salirasib
prevented tumour occurrence in a model of diethylni-
trosamine-induced hepatocarcinogenesis [18], while
others have shown an impact of low-dose salirasib on
liver fibrosis both in the preventive and the curative set-
tings [32,33]. Both observations confirm that salirasib
remains active in the liver.
Conclusions
Our results indicate that salirasib elicits a dose- and
time-dependent growth inhibitory effect in human
HCC cell lines, related to inhibition of both EGF- and
IGF-induced cell proliferation, and to a lesser extent to
induction of apoptosis. This effect is linked with ras
and mTOR inhibition, while ERK and Akt remained
activated. Furthermore, we show that salirasib also
exhibits anti-tumor activity in vivo in a mouse subcu-
taneous xenograft model. Our group has also pre-
viously described that salirasib prevents the
development of preneoplasti cl i v e rf o c ii na na n i m a l
model of diethylnitrosamine-induced hepatocarcino-
genesis [18]. These results in human HCC cell lines,
along with our previous observation of tumor preven-
tion in vivo provide a rationale for testing salirasib in
human HCC. Furthermore, investigation of combina-
tion therapies of salirasib and inhibitors of the raf/
MEK/ERK pathway, the PI3K/Akt pathway, as well as
combination with apoptosis-inducing treatments such
as conventional chemotherapy or TRAIL-agonists are
warranted in order to try to further improve the anti-
tumor effect of salirasib.
Additional material
Additional file 1: Supplementary table 1 - Western blot antibodies
and working condition
Additional file 2: Supplementary table 2 - Quantitative PCR primers
Additional file 3: Supplementary figure 1 - Salirasib modulates cell
cycle distribution. HepG2 (upper row), Huh7 (middle row), and Hep3B
(lower row) cells were seeded in 6-well plates and incubated with DMSO
(control) or 150 μM salirasib. Cell cycle distribution was assessed after 3
days of treatment. Data are presented as mean percent of cells in Sub-
G0, G0/G1, S, and G2/M phases. * P < 0.05, ** P < 0.01 and *** P < 0.001
in treated groups versus control group (n = 6 in both groups).
Additional file 4: Supplementary figure 2 - Impact of salirasib on
raf/MEK/ERK and PI3K/Akt/mTOR pathways in Huh7 cells.
Representative Western blots of 3 independent experiments of ERK, Akt,
GSK3bβ, p70, and their phosphorylated counterparts in Huh7 cells
stimulated with either EGF or IGF2 and treated with DMSO or 150 μM
salirasib for 2 hours prior to stimulation.
Additional file 5: Supplementary figure 3 - Impact of salirasib on
raf/MEK/ERK and PI3K/Akt/mTOR pathways in Hep3B cells.
Representative Western blots of 3 independent experiments of ERK, Akt,
GSK3bβ, p70, and their phosphorylated counterparts in Hep3B cells
stimulated with either EGF or IGF2 and treated with DMSO or 150 μM
salirasib for 2 hours prior to stimulation.
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